T2 Biosystems Inc (TTOO)

[stockguard]

Another article on $TTOO that needs some rubital from the bull side. This one is posted to Seeking Alpha and is super negative.

Conclusion
Our notes from the ECCMID Conference confirmed that the T2 direct from blood testing platform is prone to a significant shortcoming, which is the need to run a large number of expensive but meaningless tests on the patients with negative blood cultures. In the absence of a clear algorithm on how to pre-select patients with positive blood cultures for the T2 test (one exception is immune-compromised patients), the future of TTOO is doomed, because with its $150-$200 per panel cost it cannot compete with the relatively fast, extremely inclusive and bottom rock cheap MALDI ID test of $0.50 per test.

https://seekingalpha.com/article/4261049-research-2019-eccmid-conference-reveals-grim-outlook-t2-biosystems